Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Idioma
Tipo del documento
Publication year range
1.
Eksp Klin Farmakol ; 68(1): 25-9, 2005.
Artículo en Ruso | MEDLINE | ID: mdl-15786960

RESUMEN

Pretreatment with a selective kappa1 opioid receptor (OR) agonist (-)-U-50,488 (1 mg/kg, i.v.) prevented the development of arrhythmias induced by occlusion (10 min) and reperfusion (10 min) in ketamine anesthetized rats, while the treatment with a less active enantiomer (+)-U-50,488 in the same dose produced no such effects. Preliminary intravenous administration of a selective kappa1 OR antagonist norbinaltorphimine (9 mg/kg) fully abolished the antiarrhythmic effect of (-)-U-50,488, while the kappa2 OR antagonist quadazocine (3 mg/kg) did not eliminate this effect. The injections of norbinaltorphimine or quadazocine alone did not influence the incidence of model arrhythmias caused by the occlusion and reperfusion. It was concluded that kappa1 OR stimulation favors an increase in cardiac tolerance to the arrhythmogenic action of occlusion and reperfusion.


Asunto(s)
3,4-Dicloro-N-metil-N-(2-(1-pirrolidinil)-ciclohexil)-bencenacetamida, (trans)-Isómero/administración & dosificación , Antihipertensivos/administración & dosificación , Arritmias Cardíacas/tratamiento farmacológico , Naltrexona/análogos & derivados , Receptores Opioides kappa/agonistas , Animales , Isquemia Miocárdica/metabolismo , Reperfusión Miocárdica , Naltrexona/administración & dosificación , Antagonistas de Narcóticos/administración & dosificación , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda